OPEN ACCESS pISSN 2234-3806
eISSN 2234-3814

Table. 2.

Table. 2.

Clinical characteristics and laboratory data of patients with NAFLD according to liver fibrosis stage

Clinical characteristics Fibrosis ≤ 2 (N = 79) Fibrosis > 2 (N = 34) P
Age (yr) 36.0 (23.5; 50.5) 61.0 (54.0; 66.0) < 0.001
BMI (kg/m2) 29.1 (26.2; 32.3) 27.6 (25.1; 30.1) 0.077
DM 0.007
No 60 (75.9%) 17 (50.0%)
Yes 19 (24.1%) 17 (50.0%)
AST (µkat/L) 1.1 (0.8; 1.4) 1.3 (0.8; 2.1) 0.171
ALT (µkat/L) 1.7 (1.3; 2.7) 1.0 (0.6; 1.8) < 0.001
GGT (µkat/L) 1.1 (0.8; 1.8) 1.6 (1.1; 2.6) 0.013
Albumin (g/L) 46.8 ± 3.4 43.2 ± 4.6 < 0.001
Platelet (× 109/L) 249.0 (210.5; 294.5) 174.5 (137.0; 228.0) < 0.001
Total cholesterol (mmol/L) 5.0 (4.3; 5.7) 4.2 (3.7; 4.9) 0.005
M2BPGi (COI) 0.5 (0.3; 0.7) 1.3 (0.8; 2.2) < 0.001
NAS 4.0 (4.0; 5.0) 5.0 (4.0; 5.0) 0.314
APRI 0.7 (0.5; 0.9) 1.2 (0.8; 1.6) < 0.001
FIB-4 0.9 (0.5; 1.5) 3.9 (2.5; 5.5) < 0.001
NFS -2.9 ± 1.4 0.1 ± 1.7 < 0.001

Abbreviations: ALT, alanine aminotransferase; APRI, aspartate aminotransferaseto platelet ratio index; AST, aspartate aminotransferase; BMI, body mass index; COI, cut-off index; DM, diabetes mellitus; FIB-4, fibrosis index based on four factors; GGT, gamma-glutamyl transpeptidase; NAFLD, non-alcoholic fatty liver disease; NAS, NAFLD activity score; NFS, NAFLD fibrosis score; M2BPGi, Mac-2 binding protein glycosylation isomer.

Ann Lab Med 2021;41:302~309 https://doi.org/10.3343/alm.2021.41.3.302

© Ann Lab Med